Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Biochemical Reagents >  Agonist Inhibitors >  NS-018

NS-018

Basic information Safety Supplier Related

NS-018 Basic information

Product Name:
NS-018
Synonyms:
  • N2-[(1S)-1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine
  • Ilginatinib
  • NS018;ILGINATINIB
  • ILGINATINIB (NS-018)
  • NS-018
  • 2,6-Pyridinediamine, N2-[(1S)-1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-2-pyrazinyl-
  • JAK3,Janus kinase,Inhibitor,NS 018,JAK,JAK2,orally,Tyk2,NS018,Ilginatinib,inhibit,JAK1,bioavailable
  • Ilginatinib, 10 mM in DMSO
CAS:
1239358-86-1
MF:
C21H20FN7
MW:
389.43
Mol File:
1239358-86-1.mol
More
Less

NS-018 Chemical Properties

Boiling point:
574.1±50.0 °C(Predicted)
Density 
1.31±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
DMSO : ≥ 34 mg/mL (87.31 mM)
form 
Solid
pka
2.43±0.10(Predicted)
color 
Light yellow to yellow
More
Less

NS-018 Usage And Synthesis

Uses

Ilginatinib (NS-018) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM).

in vivo

Ilginatinib (NS-018) (12.5, 25, 50, 100 mg/kg, p.o.) potently prolongs the survival of mice and reduces splenomegaly in a mouse Ba/F3-JAK2V617F disease model[1].
Ilginatinib (NS-018) (25, 50 mg/kg, p.o.) significantly reduces leukocytosis, hepatosplenomegaly and extramedullary hematopoiesis, improves nutritional status, and prolongs survival in JAK2V617F transgenic mice

IC 50

JAK2: 0.72 nM (IC50); Tyk2: 22 nM (IC50); JAK1: 33 nM (IC50); JAK3: 39 nM (IC50)

References

[1] Nakaya Y, et al. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J. 2011 Jul;1(7):e29. DOI:10.1038/bcj.2011.29
[2] Kuroda J, et al. NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients. Leuk Res. 2014 May;38(5):619-24. DOI:10.1016/j.leukres.2014.03.001

NS-018Supplier

Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
MedChemexpress LLC
Tel
021-58955995
Email
sales@medchemexpress.cn
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696,15000506266 15000506266
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
Shanghai Rechem science Co., Ltd.
Tel
021-31433387 15618786686
Email
sales@rechemscience.com